Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

Neurology

Volumn 50, Issue 5, 1998, Pages 1273-1281

  Sorensen, P S ^a   Wanscher, B ^a   Jensen, C V ^b   Schreiber, K ^a   Blinkenberg, M ^a   Ravnborg, M ^a   Kirsmeier, H ^a   Larsen, V A ^b   Lee, M L ^c  

^a University of Copenhagen   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECZEMA; EVOKED BRAIN STEM AUDITORY RESPONSE; EVOKED MUSCLE RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; URTICARIA;

EID: 0031844370     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1273     Document Type: Article

References (34)

1. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123-1129.
2. van Doom PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical characteristics associated with improvement. Arch Neurol 1991;48:217-220.
3. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36: 838-845.
4. Kaveri SV, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 1994; 57(suppl):6-8.
5. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989;110:135-149.
6. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14:178-189.
7. Anderson UG, Bjork L, Skansen-Saphir U, Anderson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993;79: 211-216.
8. Jungi TW, Brcic M, Kuhnert P, Spycher MO, Li F, Nydegger UE. Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 1990; 82:163-169.
9. Tenser RB, Hay KA, Aberg JA. Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol 1993;50:417-420.
10. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-186.
11. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992;62: S82-S86.
12. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992;32:834-845.
13. van Engelen BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M. Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994; 57(suppl):65-68.
14. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990;27: 12-17.
15. Rothfelder U, Neu I, Pelka R. Therapy of multiple sclerosis with immunoglobulin G. Munch Med Wochenschr 1982;124: 74-78.
16. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983;22:205-212.
17. Cook SD, Troiano R, Rohowsky Kochan C, et al. Intravenous gamma globulin in progressive MS. Acta Neurol Scand 1992; 86:171-175.
18. Achiron A, Pras E, Gilad R, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-1266.
19. Fazekas F, Deisenhammer F, Strasser Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-593.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
22. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
23. Ravnborg M, Dahl K. Examination of central and peripheral motor pathways by standardized magnetic stimulation. Acta Neurol Scand 1991;84:491-497.
24. Ravnborg M, Sorensen PS, Christiansen P, Blinkenberg M. Central motor conduction as a measure of disease progression in early multiple sclerosis. Eur J Neurol 1995;2:233-241.
25. WHO Handbook for Reporting Results of Cancer Treatment. Offset public 48. Geneva: WHO, 1979.
26. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
27. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.
28. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677.
29. Hamdalla HH, Hawkes CH, Spokes EG, Bamford JM, Goulding PJ. Intravenous immunoglobulin in the Guillain-Barré syndrome. May cause severe adverse skin reactions. BMJ 1996;313:1399-1400.
30. Barucha C, McMillan JC. Eczema after intravenous infusion of immunoglobulin. Br Med J Clin Res Ed 1987;295:1141.
31. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
32. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
33. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998;50:398-402.
34. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 1994;57(suppl):21-25.